The incidence of venous thromboembolism in cervical cancer: a nationwide population-based study

• Published in: BMC research notes Vol. 5; no. 1; p. 316
• Main Authors: Tsai, Shiang-Jiun, Ruan, Ying-Xu, Lee, Ching-Chih, Lee, Moon-Sing, Chiou, Wen-Yen, Lin, Hon-Yi, Hsu, Feng-Chun, Su, Yu-Chieh, Hung, Shih-Kai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.06.2012; BioMed Central; BMC
• Subjects: Adult; Aged; Analysis; Cancer; Cardiovascular disease; Care and treatment; Case-Control Studies; Cervical cancer; Comorbidity; Complications and side effects; Demography; Female; Follow-Up Studies; Health insurance; Health Surveys; Humans; Incidence; Medical research; Middle Aged; National health insurance; Oncology, Experimental; Online databases; Prognosis; Risk Factors; Socioeconomic factors; Studies; Survival Analysis; Taiwan - epidemiology; Thromboembolism; Uterine Cervical Neoplasms - complications; Uterine Cervical Neoplasms - epidemiology; Venous Thromboembolism - epidemiology; Venous Thromboembolism - etiology; Taiwan
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/1756-0500-5-316

Venous thromboembolism (VTE) is a life-threatening condition that occurs as a complication of cervical cancer. The aim of this study was to evaluate the incidence of VTE in cervical cancer patients during a 5-year follow-up. The study analyzed data deposited between 2003 and 2008 in the National Health Insurance Research Database (NHIRD), provided by the National Health Research Institutes in Taiwan. Totally, 1013 cervical cancer patients after treatment and 2026 appendectomy patients were eligible. The Kaplan-Meier method and the Cox proportional hazards model were used to assess the VTE risk. The 5-year cumulative risk for VTE was significantly higher in the cervical cancer group than in the control group (3.3% vs 0.3%, p < 0.001). The hazard ratio for VTE was 10.14 times higher in the cervical cancer group than in the controls. The combined presence of more comorbidities was associated with a higher risk for VTE. Furthermore, cervical cancer patients without VTE had a significantly higher survival (75.3% vs 30.3%, p < 0.001). The cumulative risk of VTE was significantly higher in cervical cancer patients, and these patients also had lower survival rates. Strategies to reduce these risks need to be examined.